The study of the effectiveness of the antibacterial action of the combination of a bacteriophage with a probiotic
Keywords:bacteriophage; probiotic; lactobacilli; staphylococcus; antibiotic
Intestinal infections occupy one of the leading places in diseases of the gastrointestinal tract in humans and animals. Strains of Staphylococcus spp are one of the causative agents of an intestinal infection. When treating an intestinal infection caused by staphylococcus, antibiotics are most often used, but in recent years there has been the formation of resistance in staphylococcus strains to antibiotics that have been used for many years. One of the promising ways to solve the problem of antimicrobial resistance is the use of drugs based on bacteriophages, which have a specific effect on the disease pathogens, however, they are free of toxic and allergenic side effects on the human body and do not cause resistance.
Aim. To study the antibacterial effect of the combination of a staphylococcal bacteriophage and a probiotic based on L. acidophilus lactobacilli to different staphylococcal strains.
Materials and methods. The following bacterial strains were used in the study: St. aureus ATCC 25923 and St. epidermidis ATCC 12228. The “Polyphag Staf” staphylococcal bacteriophage (manufactured by NVK MVK, Ukraine) and the “Lactofor” probiotic (manufactured by Ananta Medicare Limited, India) based on L. acidophilus lactobacilli were selected as objects. In the study, the antibiotic “Erythromycin” in tablets of 100 mg (the manufacturer – Borschagovsky HFZ, Ukraine) was used as a reference drug. To detect the antibacterial activity to the experimental strains of St. aureus and St. epidermidis, the methods of Appelman and agar diffusion were used.
Results and discussion. It was found that when using the combination of a staphylococcal bacteriophage and a probiotic with L. acidophilus lactobacilli the level of the antibacterial activity to the experimental strains of St. aureus and St. epidermidis was higher than when using only the bacteriophage. This is probably due to the synergism of the interaction of the components of the combination of active substances proposed. It was also found that the antibacterial activity of the combination of drugs and the antibiotic erythromycin proposed was at the same level. Thus, the combination of a bacteriophage that destroys staphylococcal bacteria, has no side effects, and does not cause resistance and a probiotics that improves the microflora of the gastrointestinal tract has a number of advantages over antibiotics
in the treatment of intestinal infections caused by staphylococcal strains.
Conclusions. The studies conducted indicate the prospects of using the combination of a staphylococcal bacteriophage and a probiotic based on L. acidophilus lactobacilli for the treatment of intestinal infections caused by different staphylococcal strains.
Staphylococci in poultry intestines: a comparison between farmed and household chickens / M. Ali Syed et al. Microbiology and Food Safety. 2020. Vol. 99. Iss. 9. P. 4549–4557. DOI: https://doi.org/10.1016/j.psj.2020.05.051.
Characterization of staphylococci and their role in pathology of children / M. A. Harуfulina et al. Visnyk of Dnipropetrovsk University Biology medicine. 2014. Vol. 5, Iss. 2. Р. 115–120. DOI: https://doi.org/10.15421/021422.
Molecular diversity of methicillin-resistant and -susceptible Staphylococcus aureus detected in animals: a focus on aquatic animals / V. Silva et al. Diversity. 2021. Vol. 13, Iss. 9. P. 417. DOI: https://doi.org/10.3390/d13090417.
de Kraker M. E., Stewardson A. J., Harbarth S. Will 10 million people die a year due to antimicrobial resistance by 2050? PLOS Medicine. 2016. Vol. 13, Iss. 11. P. e1002184. DOI: https://doi.org/10.1371/journal.pmed.1002184.
Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach / M. Bassetti et al. Intensive Care Medicine. 2017. Vol. 43. Р. 1464–1475. DOI: https://doi.org/10.1007/s00134-017-4878-x.
Сучасні можливості запобігання антибіотикорезистентності: бактеріофаги як антимікробні агенти / О. К. Дуда та ін. Сімейна медицина. 2017. № 4 (72). С. 16–21.
Furfaro L., Payne M., Chang B. Bacteriophage therapy: clinical trials and regulatory hurdles. Front Cell Infect Microbiol. 2018. № 8. P. 1–7. DOI: https://doi.org/10.3389/fcimb.2018.00376.
Lin D., Koskella B., Lin H. Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World Journal of Gastrointestinal Pharmacology and Therapeutics. 2017. Vol. 8, Iss. 3. P. 162–173. DOI: https://doi.org/10.4292/wjgpt.v8.i3.162.
Abedon S. T. Information phage therapy research should report. Pharmaceuticals. 2017. Vol. 10, Iss. 2. Р. 43. DOI: https://doi.org/10.3390/ph10020043.
Phage study: effects of supplemental bacteriophage intake on inflammation and gut microbiota in healthy adults / H. P. Febvre et al. Nutrients. 2019. Vol. 11, Iss. 3. P. 666. DOI: https://doi.org/10.3390/nu11030666.
Azam A. H., Tanji Y. Peculiarities of Staphylococcus aureus phages and their possible application in phage therapy. Applied Microbiology and Biotechnology. 2019. № 103. P. 4279–4289. DOI: https://doi.org/10.1007/s00253-019-09810-2.
Antimicrobial activity of bacteriophage derived triple fusion protein against Staphylococcus aureus / N. Y. Kovalskaya et al. AIMS Microbiology. 2019. Vol. 5, Iss. 2. P. 158–175. DOI: https://doi.org/10.3934/microbiol.2019.2.158.
Fava F., Rizzetto L., Tuohy K. M. Gut microbiota and health: Connecting actors across the metabolic system. Proceedings of the Nutrition Society. 2018. Vol. 78, Iss. 2. P. 177–188. DOI: https://doi.org/10.1017/S0029665118002719.
Лях В. Р., Червецова В. Г., Кричковська А. М. Пробіотики як сучасні превентивні препарати захворювань шлунково-кишкового тракту. Хімія, технологія речовин та їх застосування. 2018. Вип. 1, № 1. С. 72–77. DOI: https://doi.org/10.23939/ctas2018.01.072.
Bacteriophages as modulator for the human gut microbiota: Release from dairy food systems and survival in a dynamic human gastrointestinal model / M. Samtlebe et al. LWT. 2018. Vol. 91. Р. 235–241. DOI: https://doi.org/10.1016/j.lwt.2018.01.033.
Phage-2 study: supplemental bacteriophages extend Bifidobacterium animalis subsp. Lactis BL04 benefits on gut health and microbiota in healthy adults / D. S. Grubb et al. Nutrients. 2020. Vol. 12, Iss. 8. P. 2474. DOI: https://doi.org/10.3390/nu12082474.
Copyright (c) 2022 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).